Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.

Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, Ji ZY, Lu PH.

PLoS One. 2012;7(6):e39655. doi: 10.1371/journal.pone.0039655. Epub 2012 Jun 29.


P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W, Lu PH.

PLoS One. 2012;7(9):e45388. doi: 10.1371/journal.pone.0045388. Epub 2012 Sep 25.


Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M.

Breast Cancer Res. 2012 May 2;14(3):R70.


Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.

Xu HY, Xu WL, Wang LQ, Chen MB, Shen HL.

PLoS One. 2014 Apr 16;9(4):e95371. doi: 10.1371/journal.pone.0095371. eCollection 2014.


14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.

Nakamura Y, Oshima K, Naoi Y, Nakayama T, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Jul;134(1):229-36. doi: 10.1007/s10549-012-1976-x.


Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis.

Yang D, Chen MB, Wang LQ, Yang L, Liu CY, Lu PH.

J Exp Clin Cancer Res. 2013 Dec 27;32:105. doi: 10.1186/1756-9966-32-105. Review.


Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.


Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M, Samonigg H, Renner W, Gerger A.

Mol Genet Genomics. 2012 Sep;287(9):755-64. doi: 10.1007/s00438-012-0715-7. Epub 2012 Aug 18.


Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.


The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.

Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.

Breast Cancer Res Treat. 2011 Oct;129(3):839-48. doi: 10.1007/s10549-011-1694-9. Epub 2011 Aug 2.


TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L.

Breast Cancer Res Treat. 2012 Apr;132(3):781-91. doi: 10.1007/s10549-011-1412-7. Epub 2011 Mar 4.


Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.


p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y.

Clin Cancer Res. 2005 Oct 15;11(20):7328-33.


Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.


Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.


TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.

Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R.

Clin Cancer Res. 2000 Jan;6(1):50-6.


Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.

Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH.

Ann Surg Oncol. 2013 Jul;20(7):2419-27. doi: 10.1245/s10434-012-2859-4. Epub 2013 Mar 21.


HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Yao L, Liu Y, Li Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Ann Oncol. 2011 Jun;22(6):1326-31. doi: 10.1093/annonc/mdq612. Epub 2010 Dec 31.


Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Cheng H, Ma B, Jiang R, Wang W, Guo H, Shen N, Li D, Zhao Q, Wang R, Yi P, Zhao Y, Liu Z, Huang T.

Mol Biol Rep. 2012 Sep;39(9):9265-74. doi: 10.1007/s11033-012-1800-z. Epub 2012 Jun 24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk